|
Status |
Public on Dec 01, 2020 |
Title |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing Expression profiling by array
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation missing |
Has this study been published? Please login to update or notify GEO. |
|
Submission date |
Aug 29, 2012 |
Last update date |
Dec 01, 2020 |
Contact name |
Barbara M Bryant |
E-mail(s) |
[email protected]
|
Organization name |
Constellation Pharmaceuticals
|
Street address |
215 First Street
|
City |
Cambridge |
State/province |
MA |
ZIP/Postal code |
02142 |
Country |
USA |
|
|
Platforms (3) |
GPL5175 |
[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [transcript (gene) version] |
GPL9115 |
Illumina Genome Analyzer II (Homo sapiens) |
GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
Samples (26)
|
|
This SuperSeries is composed of the following SubSeries:
|
GSE40472 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor (ChIP-Seq set 1) |
GSE40473 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor (ChIP-Seq set 2) |
GSE40474 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor (Exon array) |
GSE40475 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor (RNA-Seq) |
|
Relations |
BioProject |
PRJNA174125 |